


miRNA for the therapeutic treatment of tumours



Category:

Medical Sciences

Patent Ownership:

Università Politecnica delle Marche Università degli Studi di Trieste

Inventors: Massimo Bovenzi, Federica Monaco, Marco Tomasetti, Lory santarelli

Priority Date: April 20th, 2021

Patent Application Number:

102021000010001, PCT/IB2022/053644

Patent Status:

Granted in Italy, PCT active

Licensing Availability:

Available

Contacts:

Technology Transfer and Business Relations Office

E-mail: brevetti@amm.units.it

Ph: +39 040 558 3821

Brief description

The present invention falls within the field of the therapeutic treatment of tumours. More 5 specifically, the invention relates to a combination anticancer therapy, including the administration of the tumour suppressor miRNA miR-126 carried within exosomes, in combination with a further compound having the purpose of increasing the effectiveness of the tumour suppressor miRNA

Innovative aspects and main advantages

The invention allows miR-126 to be accumulated within the tumour cells, which results in growth arrest and death of the tumour cells. Advantageously and unexpectedly, the combination treatment of the invention was found to be effective both against the primary tumour, limiting its growth and development, and against cancer stem cells, inhibiting the occurrence of relapses and metastases.

Applications

- ✓ Combined anticancer therapy
- ✓ Reduction of the systemic toxicity of the treatment
- ✓ miR-126 and the exosome release inhibitor are administered in the same preparation

Potential market

Industrial production of pharmaceutical formulations for anticancer therapy

Development status

Completed experimental work in cell lines and animal models

Università degli Studi di Trieste

Piazzale Europa, 1 I - 34127 Trieste Tel. 040 558 3821 Mail: brevetti@amm.units.it www.units.it/brevetti